Above all, in RAS-driven lung cancer, inhibition of CRAF kinase activity with selective inhibitors remains suboptimal due to its less prominent role in the RAS-MAPK signaling pathway and paradoxical activation of other RAF subtypes. The gene discussed is RAF1; the disease is lung carcinoma.